• Title/Summary/Keyword: CJ-11555

Search Result 6, Processing Time 0.021 seconds

Genotoxicity Study of CJ-11555 (CJ-11555의 유전독성에 관한 연구)

  • 박지은;이성학;최재묵;김일환;김덕열;노현정;김택로;김영훈;임지웅
    • Toxicological Research
    • /
    • v.20 no.2
    • /
    • pp.153-158
    • /
    • 2004
  • To evaluate the genotoxicity of CJ-11555, an anti-cirrhotic agent, the reverse mutation test, chromosomal aberration test and in vivo micronucleus test in rats were performed. In the reverse mutation test, the treatment of CJ-11555 at doses of 33.3, 100, 333, 1000, 3330 and 5000 $\mu\textrm{g}$/plate with and without 89 did not induce mutagenicity in Salmonella typhimurium TA98, TA100, TA1535, TA1537, and Escherichia coli (E. call) WP2uvrA. In chromosomal aberration test, CJ-11555 did not induce structural a chromosomal aberration in Chinese hamster ovary (CHO) cells with and without metabolic activation at all doses. In micronucleus test, CJ-11555 did not induce any statistically significant increases in micronucleated polychromatic erythrocyte (MNPCE) at doses of 500, 1000, and 2000 mg/kg. These results suggest that CJ-11555 might not have a mutagenic potential under the conditions in this study.

Safety Pharmacology of CJ-11555 (CJ-11555의 안전성 약리실험)

  • 최재묵;이성학;김일환;박지은;김덕열;노현정;김택로;최광도;김영훈
    • Toxicological Research
    • /
    • v.20 no.2
    • /
    • pp.159-166
    • /
    • 2004
  • Safety pharmacological properties of CJ-11555, an anti-cirrhotic agent, were investigated in experimental animals and in vitro test system. CJ-11555 had no effects on normal body temperature in rats, motor coordination, chemoshock induced by pentetrazol, electric shock induced by electric shocker and writhing syndromes in mice at dose levels of 100, 300 and 1,000 mg/kg. CJ-11555 inhibited intestinal activity and prolonged hexobarbital-induced sleeping time in mice at the dose level of 1,000 mg/kg. CJ-11555 affected on general activity and behaviour tests in SD rats, such as lacrimation, ptosis, piloerection, decreased body tone, abnormal dispersion within the cage, diarrhoea, red colored faeces, slight hypothermia and decreased grooming, at the dose level of 1,000 mg/kg in rats. CJ-11555 was effected on cardiovascular and respiratory system in anesthetized beagle dogs, such as tachycardia, increase of mean blood pressure and decrease of PR interval, decrease of respiratory rate and minute volume, at dose levels of 10 and 30 mg/kg. However, these effects were also observed in vehicle treated anesthetized beagle dogs. In in vitro experiments, CJ-11555 inhibited agonists (histamine, acetyl-choline or $BaCl_2$) induced contraction of isolated guinea-pig at the concentration of 30$\times$$10^6$ M. CJ-11555 was weekly inhibited hERG channel current at concentrations of 10 and 30$\times$$10^6$ M, and $IC_{50}$ was estimated to be higher than 30${\times}$$10^6$M. Based on these results, it was concluded that CJ-11555 affected on cardiovascular and respiratory system, general activity and behaviour and hexobarbital-induced sleeping time at the dose level of 1,000 mg/kg and contraction of the smooth muscle and hERG channel current at the concentration of 30$\times$$10^6$ M.

Single and Four-Week Repeated Oral Toxicity Study of CJ-11555 in Sprague-Dawely Rats (CJ-11555의 Sprague-Dawely 랫드를 이용한 단회 및 4주 반복경구투여 독성시험)

  • 김일환;이성학;최재묵;박지은;김덕열;노현정;김택로;이상호;김영훈
    • Toxicological Research
    • /
    • v.20 no.2
    • /
    • pp.143-151
    • /
    • 2004
  • This study was to investigate single and repeated-dose toxicities of CJ-11555, an anticirrhotic agent, in Sprague-Dawley (SO) rats. In single-dose oral toxicity study, the test article were administered once by gavage to males and females at dose levels of 0 and 2,000 mg/kg. No dead animals and abnormal necropsy findings were found in control and CJ-11555 treated group. Therefore, the approximate lethal dose of CJ-11555 was considered to be higher than 2,000 mg/kg in rats. In the 4-week repeated oral toxicity study, the test article was administered once daily by gavage to male and female rats at dose levels of 0, 10, 50 and 200 mg/kg/day for 4-weeks. In clinical signs, yellow-colored urine and yellow hair coat were observed in the 50 and 200 mg/kg male and female groups. In hematology, erythrocyte count and hemoglobin were significantly decreased in the 200mg/kg male and female groups. In serum biochemistry, total cholesterol was significantly increased and aspartate aminotransferase (AST) was significantly decreased in the 50 or 200 mg/kg male and female groups. In histopathological examinations, centrilobular hepatocellular hypertrophy in the liver, congestion and pigmentation in the spleen, hyaline droplets in the kidney were observed in the 50 and 200 mg/kg male and female groups. In toxicokinetic study, CJ-11555 was dose-dependent in systemic exposure and showed better absorption in female with minimum accumulation after multidosing. Based on these results, it was concluded that the 4-week repeated oral dose of CJ-11555 resulted in the suppression of AST activity and centrilobular hepatocellular hypertrophy in both sexes at a dose level of 50 or 200 mg/kg/day. The target organ was estimated to be liver, spleen and male's kidney. The no-observed-adverse-effect level (NOAEL) for CJ-11555 in rats following gavage for at least 4-week is 10 mg/kg/day.

Pharmacokinetics of CJ-11555:Improvement of Bioavailability

  • Noh, Hyun-Jung;Kim, Il-Hwan;Choi, Jae-Mook;Kim, Deog-Yeor;Park, Jie-Eun;Choi, Kwang-Do;Yeon, Kyu-Jeong;Lee, Sung-Hak;Kim, Taek-Rho
    • Proceedings of the PSK Conference
    • /
    • 2003.10b
    • /
    • pp.241.1-241.1
    • /
    • 2003
  • Purpose: The objective of the study was to elucidate the pharmacokinetics of CJ-11555, anti-cirrhotic agent, in different physical properties and vehicles. Methods: 8-week-old male intact rats were administered CJ-11555 either intravenously (20 mg/0.6 mL/kg, NMP:PEG400, 1:1) or orally (50 mg/2 mL/kg, various vehicles). Different particle sizes of CJ-11668 and various vehicles were applied to characterize CJ-11555 in vivo. Following the administration in rats, the plasma concentrations were determined by HPLC. (omitted)

  • PDF

Toxicokinetics of CJ-11555: Gender Difference and Minimum Accumulation

  • Kim, Il-Hwan;Noh, Hyun-Jung;Park, Jae-Mook;Kim, Deog-Yeor;Park, Jie-Eun;Lee, Sung-Hak;Kim, Taek-Rho;Kim, Jin-Wan;Kim, Young-Hoon
    • Proceedings of the PSK Conference
    • /
    • 2003.10b
    • /
    • pp.243.2-244
    • /
    • 2003
  • Purpose: This study evaluated gender differences and extents of accumulation on chronic dose of CJ-1l555 using rats. Method: 0, 10, 50 and 200 mg/kg/day of CJ-11555 (0.5% CMC) were orally administered to rats for 28 days and observed toxicokinetic parameters. Plasma concentrations were analyzed by LC-MS/MS Result: Exposure to CJ-11555 increased with the increase in dose level for both sexes. Mean concentrations at 10 and 50 mg/kg/day were generally similar an Days 1 and 28, but were generally highter on Day 28 than on Day 1 at 200 mg/kg/day. (omitted)

  • PDF